Skip to main content
. 2013 Feb 25;2:68. doi: 10.1186/2193-1801-2-68

Table 2.

Treatment related characteristics

Variable Breast cancer survivors (n = 30)
Current Aromatase Inhibitor 14/30 (47%)
Current Tamoxifen 1/30 (3%)
Past Aromatase Inhibitors 4/30 (13%)
Past Tamoxifen 1/30 (3%)
Post-menopausal 28/30 (93%)
Adriamycin/Epirubicin 24/30 (80%)
Herceptin 8/30 (27%)
Left chest radiation 12/30 (40%)